Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it will participate in the upcoming BIO-Europe 2024 conference in Stockholm.
The event will allow Tiziana to engage with industry leaders, potential collaborators, and investors, emphasizing its recent clinical advancements, particularly data from its combination study involving Ozempic, a GLP-1 agonist.
The BIO-Europe conference is recognized as a premier event in the biopharma industry, attracting key players from around the globe.
"The BIO-Europe conference offers an ideal opportunity to highlight our latest clinical findings, including the positive data from our GLP-1 combination study,” said Ivor Elrifi, CEO of Tiziana Life Sciences.
“We will be engaging with prospective partners in Stockholm to explore collaborations that will further accelerate our mission of delivering groundbreaking therapies to patients worldwide. “We look forward to further advancing our Phase 2 studies following on from the closing of a successful fundraise.”